The reductions come as chief executive Mike Doustdar attempts to revive the weight-loss drug pioneer’s market position amid intensifying competition and upcoming patent expirations for core blockbusters. Workforce Reductions and Cost-Cutting Measures Novo shed 13,000 jobs during the past year as part of an ongoing cost-reduction strategy, according to financial disclosures from the company. The … Read more
Administering an experimental small interfering RNA therapy alongside the GLP-1 drug semaglutide cuts muscle loss by nearly half while enhancing fat reduction in mice, according to a study published September 22 in the Proceedings of the National Academy of Sciences. Developed by researchers at the Northwestern University Feinberg School of Medicine and biotech firm Ionis … Read more
The UK medicines regulator has authorized Eli Lilly’s once-daily weight-loss pill Foundayo for weight management and type 2 diabetes, making Britain the first European country to clear the oral GLP-1 treatment. The drug is not yet available on the NHS pending a health technology appraisal. Eli Lilly has secured a major regulatory milestone in Europe … Read more
The European Commission recently approved the oral version of Wegovy (semaglutide 25 mg) for adults with obesity and at least one weight-related comorbidity, according to Novo Nordisk. This regulatory milestone makes Wegovy the first GLP-1 tablet authorized for weight management in the European Union, following previous approvals in the United States, United Kingdom, United Arab … Read more
Novo Nordisk (NVO) and Pfizer (PFE) stand out as the cheapest large-cap healthcare names in 2026, trading at forward price-to-earnings multiples of 14x and 8x, respectively. Both companies currently grapple with significant headwinds—including drug pricing reforms and patent cliffs—but maintain strong free cash flow and upcoming data catalysts, according to data from 24/7 Wall St. … Read more
Ozempic’s Patent Cliff: A Global Shift in Diabetes and Weight Loss Treatment A pivotal moment is unfolding in the pharmaceutical landscape as patent protections for semaglutide – the active ingredient in both Ozempic (for diabetes) and Wegovy (for weight loss) – expire in key global markets. This expiration, beginning Saturday, March 28, 2026, is poised … Read more
FDA Scrutinizes Novo Nordisk: Reporting Lapses and Rising Safety Concerns with Ozempic & Wegovy The FDA recently issued a warning letter to Novo Nordisk, the manufacturer of Ozempic and Wegovy, citing failures to adequately report potential adverse effects and deaths linked to the popular GLP-1 medications. This action underscores growing scrutiny surrounding these drugs as … Read more
Weight-Loss Drugs and Vision Loss: What the Latest Research Reveals Recent studies are raising concerns about a potential link between semaglutide-based weight-loss medications, like Wegovy and Ozempic, and an increased risk of ischemic optic neuropathy (ION), a condition that can lead to vision loss. While the research is preliminary, it’s prompting closer scrutiny of these … Read more
FDA Scrutiny of Ozempic: A Sign of Increased Oversight for Weight Loss Drugs? Novo Nordisk, the maker of the popular diabetes and weight loss drug Ozempic, is facing renewed scrutiny from the U.S. Food and Drug Administration (FDA). A warning letter issued on March 5th highlighted concerns over the company’s reporting procedures for potential side … Read more
Weight Loss Drug Wars: Truce Between Novo Nordisk and Hims & Hers Signals Shift in Market A significant development is unfolding in the weight loss industry. Novo Nordisk, the manufacturer of Ozempic and Wegovy, and telehealth provider Hims & Hers have reached an agreement, ending a contentious legal battle and reshaping how patients access these … Read more